FY2024 Earnings Forecast for APLS Issued By William Blair

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Analysts at William Blair decreased their FY2024 earnings estimates for shares of Apellis Pharmaceuticals in a research note issued on Tuesday, November 5th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of ($1.71) per share for the year, down from their previous forecast of ($1.25). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.40) per share. William Blair also issued estimates for Apellis Pharmaceuticals’ Q4 2024 earnings at ($0.41) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.16) EPS and FY2025 earnings at ($1.07) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The business had revenue of $196.83 million for the quarter, compared to analysts’ expectations of $200.00 million. During the same quarter in the prior year, the company posted ($1.17) EPS. The business’s revenue for the quarter was up 78.3% on a year-over-year basis.

Several other equities analysts also recently issued reports on the stock. Citigroup cut their price objective on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday. Oppenheimer decreased their price target on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a report on Wednesday. Scotiabank cut their target price on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a research report on Wednesday. Piper Sandler lowered their price target on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a research report on Wednesday. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $25.00 price objective on shares of Apellis Pharmaceuticals in a report on Monday, November 4th. Six equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $51.06.

Apellis Pharmaceuticals Trading Up 4.3 %

Apellis Pharmaceuticals stock opened at $29.98 on Friday. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.18 and a current ratio of 5.08. The stock has a market cap of $3.65 billion, a PE ratio of -10.94 and a beta of 0.87. The stock has a 50-day moving average of $31.02 and a two-hundred day moving average of $37.02. Apellis Pharmaceuticals has a one year low of $24.34 and a one year high of $73.80.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the completion of the transaction, the director now owns 100,000 shares in the company, valued at approximately $3,623,000. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 6.80% of the stock is owned by company insiders.

Institutional Trading of Apellis Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in APLS. Wolverine Asset Management LLC acquired a new stake in Apellis Pharmaceuticals in the 3rd quarter valued at $27,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Apellis Pharmaceuticals during the first quarter valued at $89,000. Capital Performance Advisors LLP acquired a new stake in shares of Apellis Pharmaceuticals in the third quarter valued at about $56,000. KBC Group NV increased its stake in shares of Apellis Pharmaceuticals by 34.8% during the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after purchasing an additional 679 shares in the last quarter. Finally, nVerses Capital LLC raised its position in shares of Apellis Pharmaceuticals by 300.0% during the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock worth $107,000 after purchasing an additional 2,100 shares during the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).